Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

An Israeli Biotech Bull Lists On The Nasdaq

Mar 23, 2017 • 12:35 PM EDT
Untitled design (62).png
4 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Although Israel is known for its advanced weaponry and military defense systems, the country is also a leader in scientific research focused on cannabis. Scientists in Israel have been researching the benefits associated with cannabis for the last 50 years and the country’s pro-cannabis standpoint has made it attractive to pharmaceutical and biotech companies.

The growth of the cannabis industry has provided investors with the opportunity to invest in Israeli cannabis companies that trade on the United States stock market.

Although these opportunities are attractive to a lot of investors, many do not want to invest in an OTC-traded company….and now they do not need to do so

A Biotech to Bet on

The market just received a new IPO from a biotech firm that is taking an approach similar to companies such as GW Pharmaceuticals (GWPH) and Zynerba Pharmaceuticals (ZYNE).

The company, Therapix Biosciences Ltd. (TRPX: Nasdaq) was founded in 2004 and listed on the Tel Aviv Stock Exchange (TASE) in early 2014.

TRPX rallied almost 50% during its first day trading on the Nasdaq exchange and the shares continue to trend higher this morning.

About Therapix Biosciences

Therapix Biosciences is a specialty clinical-stage pharmaceutical company led by a team of experienced executives and scientists focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

The company plans to use the net proceeds from its IPO to advance its two leading product candidates for its upcoming planned Phase II clinical trials and for working capital and other general corporate purposes.

Therapix has initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol):  

  • THX-TS01 targeted to the treatment of Tourette Syndrome
  • THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments.

THX-TSO1, Therapix’s leading product candidate is created by using dronabinol and Palmitoylethanolamide (PEA). Dronabinol is a man-made form of cannabis and is the name of the psychoactive compound in cannabis (THC). PEA is a fatty acid that has a natural attraction to the GPR55 and GPR119 cannabinoid receptors. The fatty acid does not bind to the primary endocannabinoid receptors, CB1 and CB2.

A New and Different Biotech Opportunity

Investors and financial institutions have been patiently waiting for new Nasdaq-traded biotech cannabis investment opportunities and we are favorable on the opportunity provided by Therapix.

We expect Therapix to be a profitable investment due to the strong demand for cannabis related investments from investors and financial institutions who want to invest in companies that trade on a national stock exchange (not the OTC). 


Important Investor Disclosures

Disclosure.  Compensated Affiliate.  This report was authored by and is property of StoneBridge Partners LLC.  All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional adviceregarding any and all securities investments.  This report is intended for informational purposes only.  StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC.  StoneBridge Partners LLC receives 

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.